New combo flu pill put to the test in healthy volunteers

NCT ID NCT07645534

Recruiting now Knowledge-focused Sponsor: Valenta Pharm JSC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new combination capsule (Ingavirin Forte) that contains two active ingredients against the standard single-ingredient Ingavirin. The goal is to see how the body processes each version and whether the combination is safe. Thirty-six healthy adults will take both versions at different times, under fasting and fed conditions, so researchers can compare drug levels and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Ingavirin Forte (imidazolylethanamide of pentanedioic acid and XC9)

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza viral respiratory tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE RESPIRATORY VIRAL INFECTIONS INFLUENZA

Contacts and locations

Show contact details

Locations

Federal Budgetary Institution of Science "North-West Public Health Research Center"
RECRUITING

Saint Petersburg, 191036, Russia

Contact Phone: •••-•••-•••• Email: •••••@•••••